The DOI matches its Crossref record; 91 of the 95 references it cites were found in a registry or an index; 93 of the 201 sources its claims cite were checked for support.
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Open accessAbstract
This critical review identifies pharmacokinetic, dose, and temporal conflicts that hinder the translation of theranostic nanoplatforms for AD.
Overview
CoChat Summary
## TL;DR
This is a critical review arguing that current Alzheimer’s disease theranostic nanoplatforms are constrained by three fundamental conflicts: pharmacokinetic, dose, and temporal mismatches. The authors conclude that the “one particle for everything” model has not translated clinically and recommend alternative strategies such as preclinical “hit-and-clear” intervention, separate diagnostic/therapeutic particles, and theranostic monitoring.
## Key findings
- The review identified three core conceptual conflicts in AD theranostics:
- Pharmacokinetic conflict: diagnostics need rapid accumulation and clearance, while therapy needs prolonged retention.
- Dose conflict: diagnostic and therapeutic doses often differ by orders of magnitude; the paper states 13–400-fold or greater disparities, and in one example diagnostic and therapeutic doses for SPIONs were reported as 5860 mg/kg vs 25–100 mg/kg.
- Temporal conflict: imaging is typically short-term, but AD therapy is chronic/lifelong, making repeat diagnostics difficult because particles can generate persistent background signals.
- The authors say only 23 studies were selected for their representative analysis of existing nanotheranostic systems for AD.
- Brain delivery is reported as very limited in the few studies with quantitative data, with accumulation of only 1.94% ID/g for a nanosweeper system and 1.12–1.57% ID/g for mesoporous NPs with dual targeting.
- The paper highlights a methodological trap: much of the field focuses on mature Aβ fibrils, even though the authors argue soluble Aβ oligomers are the more toxic species and should be prioritized.
## Methods
- This is a critical review, not a systematic review; the authors explicitly say they chose a conceptual analysis rather than an exhaustive catalog.
- They performed a literature search in PubMed, Scopus, and Web of Science covering January 2015 to December 2024, using AD/nanomedicine/theranostic keywords.
- Inclusion criteria: original peer-reviewed research on AD nanoplatforms with dual diagnostic and therapeutic functionality in in vitro or in vivo models; exclusion criteria included diagnosis-only, therapy-only, reviews, conference abstracts, editorials, book chapters, and non-AD neurodegenerative studies.
## Limitations
- The authors state the sample was selective rather than exhaustive, because the goal was conceptual analysis rather than complete coverage.
- They note that heterogeneous experimental models, dosing protocols, efficacy measures, and units prevent correct quantitative comparison across studies.
- They also acknowledge that negative results are often not publicly available, which may distort the apparent success of approaches.
- Evident from the text: many conclusions rest on a small set of representative studies, and several cited studies are preclinical only, often in models such as transgenic mice or *C. elegans*, limiting direct clinical inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
65 Valid · 7 Not valid · 54 Not checked · 103 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Liu and co-authors [67] provide quantitative dissociation constants for oligomers (68.3 nM) and fibrils (112.5 nM) of Aβ”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.4. Methodological Trap: Fibrils vs. Oligomers
What the sources say
- Disputedcites [67] Liu, 2022, Dual-Targeted Magnetic Mesoporous Silica Nanoparticles Reduce Brain Amyloid-β Burden via Depolymerization and Intestinal Metabolism, Theranostics sourceExperimental — accuracy not yet measured
The Characterization of HA-MMSN-1F12 section reports an oligomer-binding Kd of 1.27 ± 0.34 nM for HA-MMSN-1F12, not 68.3 nM. It gives no fibril Kd of 112.5 nM; a search for those values and for fibril dissociation constants found no matching passage in our copy. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
- Also stated in: § 2.2. Hyperphosphorylated Tau-Protein · plain
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51]”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.2. Hyperphosphorylated Tau-Protein
What the sources say
- Not checked — no full text of the sourcecites [49] Mullane, 2018, Alzheimer’s Disease (AD) Therapeutics—2: Beyond Amyloid—Re-Defining AD and Its Causality to Discover Effective Therapeutics, Biochem. Pharmacol. source
- Partly supportedcites [51] Nisbet, 2015, Tau Aggregation and Its Interplay with Amyloid-β, Acta Neuropathol. sourceExperimental — accuracy not yet measured
The section “Synergistic roles of Aβ and tau in AD” (page unavailable) links increased tau aggregation to dendritic spine loss and accelerated cognitive impairment, and reports improved memory in mice when tau is reduced without changing Aβ levels. The copy does not establish that hyperphosphorylated tau accumulation correlates more robustly than Aβ with cognitive decline or neuronal loss. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.2. Hyperphosphorylated Tau-Protein · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Current AD therapy is limited to symptomatic treatment [13].”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 1. Introduction
What the sources say
- Supportedcites [13] Cummings, 2018, Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes, Clin. Transl. Sci. source
Lesson 4 describes symptomatic therapies as providing short-term improvement, while Lesson 10 says that no working model has guided successful disease-modifying therapy development. Together with the Summary’s description of successful AD drug development as an unmet need, these passages support the claim in the paper’s 2018 context. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The most toxic forms of Aβ are not mature fibrils, but soluble oligomers [65].”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.4. Methodological Trap: Fibrils vs. Oligomers
What the sources say
- Supportedcites [65] Francisco, 2024, Recent Advances in Fluorescent Theranostics for Alzheimer’s Disease: A Comprehensive Survey on Design, Synthesis, and Properties, ACS Omega source
The Amyloid-β Targeting Theranostics section explicitly says that cumulative clinical and nonclinical evidence supports soluble Aβ oligomers being more neurotoxic than insoluble Aβ fibrils in plaques. This directly supports the citing sentence’s comparison with mature fibrils. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“pathological changes in the brain begin to accumulate many years before the appearance of clinical symptoms [12]”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 1. Introduction
What the sources say
- Partly supportedcites [12] Rasmussen, 2019, Alzheimer’s Disease—Why We Need Early Diagnosis, Degener. Neurol. Neuromuscul. Dis. sourceExperimental — accuracy not yet measured
The ‘Improving Alzheimer’s Disease Diagnosis Rates’ section says that people with preclinical Alzheimer’s disease can have signs of pathology despite having no cognitive symptoms. It does not establish that those pathological changes begin accumulating many years before clinical symptoms. Its reference to up to eight years concerns detection of mild cognitive impairment before dementia symptoms, not pathology before any clinical symptoms; page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
118 more claims · 34 with their cited sources checked
Create a free account to see all 229 claims and to verify the 4 references still open.
- It may state two separate claims as one. 93
- Probably not a substantial claim. 19
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Furthermore, all existing methods of AD treatment are used lifelong, since the disease has a chronic progressive course with a preclinical phase starting 10–20 years before the onset of symptoms, and an inevitable fatal outcome within 5–12 years after their onset [90].”
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Gold nanoparticles in biomedical applications: recent advances and perspectives
Dykman, L., & Khlebtsov, N. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15166e · Cited by 1,961
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“For example, bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47], while crenezumab also failed to meet primary endpoints [13].”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“For example, bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47], while crenezumab also failed to meet primary endpoints [13].”
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561 · cited 1×
“Each class possesses unique properties: lipid particles (liposomes, exosomes) offer biocompatibility [23–25]; polymeric particles (Poly(lactic-co-glycolic acid) (PLGA), dendrimers) provide biodegradability and functionalization [19,26]; superparamagnetic iron oxide Nps (SPIONs) enable MRI contrast…”
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996 · cited 1×
“The key success factor is the presence of solid tumors with disrupted vascular architecture, which provides a pronounced enhanced permeability and retention (EPR) effect [32,34].”
Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820 · cited 2×
“Thus, non-amyloid targets—such as tau, inflammation, and oxidative stress—warrant priority [7].”
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“Consequently, A β ’s primacy in pathogenesis is increasingly questioned [48].”
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
Jia, J., Wei, C., Chen, S., Li, F., Tang, Y., Qin, W., Zhao, L., Jin, H., Xu, H., Wang, F., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.12.006 · Cited by 752 · cited 1×
“The disease not only significantly reduces the quality of life of patients and their families but also imposes a substantial economic strain [3].”
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
Kwon, H. J., Cha, M.-Y., Kim, D., Kim, D. K., Soh, M., Shin, K., Hyeon, T., & Mook-Jung, I. (2016) · ACS Nano · doi:10.1021/acsnano.5b08045 · Cited by 655 · cited 1×
“Of particular interest is the use of Nps with antioxidant activity [59] (Figure 1), due to the important role of oxidative stress in the pathological changes in AD.”
Using Graphene Oxide High Near‐Infrared Absorbance for Photothermal Treatment of Alzheimer's Disease
Li, M., Yang, X., Ren, J., Qu, K., & Qu, X. (2012) · Advanced Materials · doi:10.1002/adma.201104864 · Cited by 535 · cited 2×
“Continuous diagnostics enable real-time efficacy monitoring while minimizing systemic toxicity [30].”
Alzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen, J., & Langerman, H. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s228939 · Cited by 501
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490 · cited 1×
“Nevertheless, despite the promise of targeting neuroinflammation and ROS, it remains unclear whether microglial activation is a primary triggering mechanism or merely a consequence of protein aggregate accumulation [60].”
In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease
Kuhl, D. E., Koeppe, R. A., Minoshima, S., Snyder, S. E., Ficaro, E. P., Foster, N. L., Frey, K. A., & Kilbourn, M. R. (1999) · Neurology · doi:10.1212/wnl.52.4.691 · Cited by 387 · cited 1×
“PET imaging of cholinergic neurons paired with targeted acetylcholinesterase inhibitor delivery shows promise [61,62].”
Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation
Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368 · cited 1×
“Hallmarks include extracellular senile plaques composed of β -amyloid (A β ) and intracellular neurofibrillary tangles of hyperphosphorylated tau protein [4].”
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363 · cited 1×
“PET imaging of cholinergic neurons paired with targeted acetylcholinesterase inhibitor delivery shows promise [61,62].”
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360 · cited 1×
“Alongside protein aggregation, mitochondrial dysfunction—with reactive oxygen species (ROS) accumulation and neuroinflammation driving microglial activation—plays a central role in AD pathogenesis [56].”
Tau Aggregation and Its Interplay with Amyloid-β
Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · cited 1×
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than A β [49,51], making it a promising agent for targeted therapy delivery.”
Han, L., & Jiang, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.023 · Cited by 358 · cited 2×
“As Han and Jiang [88] review, AD BBB integrity varies by disease stage rather than remaining static.”
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318 · cited 1×
“Each class possesses unique properties: lipid particles (liposomes, exosomes) offer biocompatibility [23–25]; polymeric particles (Poly(lactic-co-glycolic acid) (PLGA), dendrimers) provide biodegradability and functionalization [19,26]; superparamagnetic iron oxide Nps (SPIONs) enable MRI contrast…”
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298 · cited 2×
“For example, bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47], while crenezumab also failed to meet primary endpoints [13].”
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
Cheng, K. K., Chan, P. S., Fan, S., Kwan, S. M., Yeung, K. L., Wáng, Y.-X. J., Chow, A. H. L., Wu, E. X., & Baum, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.005 · Cited by 293 · cited 1×
“The accumulation of A β in the brain can be visualized in vivo using PET with FDA-approved radiopharmaceuticals [27,41]; approaches aimed at MRI diagnostics using magnetic Nps are also actively used [42].”
Dubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S., & Cummings, J. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01314-6 · Cited by 288 · cited 1×
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8–10].”
Tau PET imaging: present and future directions
Saint-Aubert, L., Lemoine, L., Chiotis, K., Leuzy, A., Rodriguez-Vieitez, E., & Nordberg, A. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0162-3 · Cited by 282 · cited 1×
“Visualization employs PET tracers [52,53] and MRI contrast agents [54], though studies lag behind A β imaging.”
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280 · cited 10×
“…due to the high flexibility of chemical design: the polymer matrix allows for the encapsulation of various therapeutic agents (e.g., methylene blue [64], cyclophosphamide [70], curcumin [71]), and the surface can be easily functionalized with targeting ligands and contrast agents for MRI or…”
InfluentialTargeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
Jo, S. D., Ku, S. H., Won, Y.-Y., Kim, S. H., & Kwon, I. C. (2016) · Theranostics · doi:10.7150/thno.15335 · Cited by 218 · cited 2×
“To date, theranostics has been most successfully implemented in oncology [32].”
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
Burkett, B. J., Bartlett, D. J., McGarrah, P. W., Lewis, A. R., Johnson, D. R., Berberoğlu, K., Pandey, M. K., Packard, A. T., Halfdanarson, T. R., Hruska, C. B., et al. (2023) · Radiology: Imaging Cancer · doi:10.1148/rycan.220157 · Cited by 217 · cited 1×
“Related to these properties, several theranostic drugs have already been approved by the FDA for cancer therapy [35].”
Brain Amyloid Imaging — FDA Approval of Florbetapir F18 Injection
Yang, L., Rieves, D., & Ganley, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1208061 · Cited by 201 · cited 1×
“The accumulation of A β in the brain can be visualized in vivo using PET with FDA-approved radiopharmaceuticals [27,41]; approaches aimed at MRI diagnostics using magnetic Nps are also actively used [42].”
Pene, F., Courtine, E., Cariou, A., & Mira, J.-P. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181921349 · Cited by 193 · cited 1×
“The term “theranostics” was introduced into scientific use in 2002 by John Funkhouser to describe agents that can be used simultaneously for diagnosis and therapy [18].”
A Self-Destructive Nanosweeper That Captures and Clears Amyloid β-Peptides
Luo, Q., Lin, Y.-X., Yang, P.-P., Wang, Y., Qi, G.-B., Qiao, Z.-Y., Li, B.-N., Zhang, K., Zhang, J.-P., Wang, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04255-z · Cited by 191 · cited 6×
“This achieved 40–60% A β reduction in mouse brains (soluble A β : 585 to 190 ng/mg; insoluble: 1539 to 914 ng/mg) [44].”
InfluentialDupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182 · cited 1×
“The translocator protein, a hallmark of activated microglia, serves as the gold standard for PET-based neuroinflammation imaging [57].”
Hu, B., Dai, F., Fan, Z., Ma, G., Tang, Q., & Zhang, X. (2015) · Advanced Materials · doi:10.1002/adma.201502227 · Cited by 155 · cited 10×
“A significant portion of the studies use MRI with contrast agents based on gadolinium [70,71], SPIONs [58,63,73,83], or manganese ions [72], reflecting the researchers’ desire to create platforms potentially applicable in clinical practice.”
InfluentialAmiri, H., Saeidi, K., Borhani, P., Manafirad, A., Ghavami, M., & Zerbi, V. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn4001582 · Cited by 131 · cited 1×
“Numerous preclinical studies target amyloid with theranostic nanoplatforms [39,40].”
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124 · cited 6×
“The use of such a diagnostic–therapeutic platform allows for real-time tracking of pharmacokinetics and biodistribution, as well as local action directly in the area of the pathological focus [20].”
InfluentialCano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122 · cited 1×
“Modern diagnostics is shifting towards detecting the disease at the preclinical stage using biomarkers [94], which creates a demand for strategies capable not only of treating but also of monitoring therapy effectiveness in dynamics.”
Zhang, R., Li, Y., Hu, B., Lu, Z., Zhang, J., & Zhang, X. (2016) · Advanced Materials · doi:10.1002/adma.201600554 · Cited by 116 · cited 2×
“Individual studies implement more complex therapeutic strategies, including the chelation of metal ions [69], photothermal disruption of fibrils under the action of near-infrared radiation [29,81], control of stem cell differentiation [73], or activation of microglial phagocytosis [63].”
Li, Y., Xu, D., Ho, S.-L., Li, H.-W., Yang, R., & Wong, M. S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.047 · Cited by 102 · cited 7×
“The most common approach is the inhibition of A β aggregation and the disaggregation of already formed fibrils [29,68,77,79,81,84].”
InfluentialEbell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
The application of exosomes and Exosome-nanoparticle in treating brain disorders
Salarpour, S., Barani, M., Pardakhty, A., Khatami, M., & Chauhan, N. P. S. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118549 · Cited by 97
Li, M., Guan, Y., Zhao, A., Ren, J., & Qu, X. (2017) · Theranostics · doi:10.7150/thno.18459 · Cited by 90
Zhao, J., Yin, F., Ji, L., Wang, C., Shi, C., Liu, X., Yang, H., Wang, X., & Kong, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c11064 · Cited by 88 · cited 1×
“Visualization employs PET tracers [52,53] and MRI contrast agents [54], though studies lag behind A β imaging.”
Ruan, Y., Xiong, Y., Fang, W., Yu, Q., Mai, Y., Cao, Z., Wang, K., Lei, M., Xu, J., Liu, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01524-4 · Cited by 85 · cited 8×
“A significant portion of the studies use MRI with contrast agents based on gadolinium [70,71], SPIONs [58,63,73,83], or manganese ions [72], reflecting the researchers’ desire to create platforms potentially applicable in clinical practice.”
InfluentialCui, Z., Bu, W., Fan, W., Zhang, J., Ni, D., Liu, Y., Wang, J., Liu, J., Yao, Z., & Shi, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.056 · Cited by 83 · cited 5×
“Similarly, Cui et al. [69] constructed UCHQs—upconversion luminescence Nps (NaYF 4 :Yb/Er/Tm) coated with DSPE-PEG and functionalized with 8-hydroxyquinoline-2-carboxylic acid (HQC).”
InfluentialMolecular basis of β-amyloid oligomer recognition with a conformational antibody fragment
Morgado, I., Wieligmann, K., Bereza, M., Rönicke, R., Meinhardt, K., Annamalai, K., Baumann, M., Wacker, J., Hortschansky, P., Malešević, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206433109 · Cited by 80 · cited 3×
“Structural studies highlight their differences: heterogeneous, disordered oligomers contrast with ordered fibrils [66].”
InfluentialQu, F., Yang, M., & Rasooly, A. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02659 · Cited by 79 · cited 1×
“Therapeutic effects arise from aggregation inhibitors (e.g., methylene blue), physical disruption methods, and agents promoting autophagy or A β clearance [44,45].”
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Engineering Theranostic Nanovehicles Capable of Targeting Cerebrovascular Amyloid Deposits
Agyare, E. K., Jaruszewski, K. M., Curran, G. L., Rosenberg, J. T., Grant, S. C., Lowe, V. J., Ramakrishnan, S., Paravastu, A. K., Poduslo, J. F., & Kandimalla, K. K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.010 · Cited by 71
Sun, H., Zhong, Y., Zhu, X., Liao, H., Lee, J., Chen, Y., Ma, L., Ren, J., Zhao, M., Tu, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10690 · Cited by 70 · cited 1×
“…delivery, specific antibodies or vectors are also used, and the therapeutic effect is achieved by suppressing aggregation processes and enzymes that mediate hyperphosphorylation, stimulating autophagy, and using physical methods such as photodynamic dissociation of aggregates [21,55] (Figure 1).”
Kurz, S. C., Zan, E., Cordova, C., Troxel, A. B., Barbaro, M., Silverman, J. S., Snuderl, M., Zagzag, D., Kondziolka, D. S., Golfinos, J. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2533 · Cited by 65 · cited 1×
“For example, in patients with intracranial meningioma, 68 Ga-DOTATATE PET is used for diagnostic imaging, while 177 Lu-DOTATATE provides targeted radionuclide therapy—both sharing the same ligand (DOTATATE) targeting somatostatin receptor type 2 (SSTR2) [95].”
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64 · cited 6×
“As shown in the review by Moorthy and co-authors [19], such approaches include: 1.”
InfluentialMultimodal Nanoprobes to Target Cerebrovascular Amyloid in Alzheimer’s Disease Brain
Jaruszewski, K. M., Curran, G. L., Swaminathan, S. K., Rosenberg, J. T., Grant, S. C., Ramakrishnan, S., Lowe, V. J., Poduslo, J. F., & Kandimalla, K. K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.075 · Cited by 64 · cited 7×
“A significant portion of the studies use MRI with contrast agents based on gadolinium [70,71], SPIONs [58,63,73,83], or manganese ions [72], reflecting the researchers’ desire to create platforms potentially applicable in clinical practice.”
InfluentialKochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60 · cited 1×
“Targeting employs A β -specific ligands (e.g., anti-amyloid antibodies, curcumin, Congo red, thioflavin) [43].”
Synergistic Inhibitory Effect of GQDs–Tramiprosate Covalent Binding on Amyloid Aggregation
Liu, Y., Xu, L.-P., Wang, Q., Yang, B., & Zhang, X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00439 · Cited by 58 · cited 1×
“The pharmacokinetics of such a system is determined by the nanocarrier, which ensures the delivery of both components across the BBB and their joint accumulation in the target area [87].”
Liu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55 · cited 8×
“A significant portion of the studies use MRI with contrast agents based on gadolinium [70,71], SPIONs [58,63,73,83], or manganese ions [72], reflecting the researchers’ desire to create platforms potentially applicable in clinical practice.”
InfluentialWang, W., Liu, M., Gao, W., Sun, Y., & Dong, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c17267 · Cited by 53 · cited 10×
“Wang et al. [68] showed the advantage of the developed Nps in detecting toxic oligomeric forms of beta-amyloid, compared to thioflavin.”
InfluentialWang, W., Lin, X., Dong, X., & Sun, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.029 · Cited by 53 · cited 4×
“Upon closer examination, CD-based platforms [77–80] exemplify parallel function combinations rather than true synergy, as their imaging and therapeutic capabilities operate independently without mutual enhancement.”
InfluentialQuantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53 · cited 3×
“For QD, diagnostic concentrations range from 50 nM to 15 mg/kg, while therapeutic ones vary from 5 µ M to 200 µ g/kg [91].”
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52 · cited 1×
“The high interest in these approaches is confirmed by the exponential growth in the number of publications over the past 10–15 years [21,31].”
Tau‐targeting nanoparticles for treatment of Alzheimer's disease
Pawar, S., Rauf, M. A., Abdelhady, H. G., & Iyer, A. K. (2024) · Exploration · doi:10.1002/exp.20230137 · Cited by 52 · cited 1×
“Visualization employs PET tracers [52,53] and MRI contrast agents [54], though studies lag behind A β imaging.”
Liu, D., Li, W., Jiang, X., Bai, S., Liu, J., Liu, X., Shi, Y., Kuai, Z., Kong, W., Gao, R., et al. (2019) · Theranostics · doi:10.7150/thno.30649 · Cited by 49 · cited 5×
“Individual studies implement more complex therapeutic strategies, including the chelation of metal ions [69], photothermal disruption of fibrils under the action of near-infrared radiation [29,81], control of stem cell differentiation [73], or activation of microglial phagocytosis [63].”
InfluentialDerakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48 · cited 1×
“Rather, they necessitate abandoning the “one particle for everything” paradigm in favor of flex-https ible, coordinated strategies where diagnostics and therapy operate synergistically yet independently within separate carriers [93].”
Vinod, C., & Jena, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.612692 · Cited by 45 · cited 1×
“The risk of chronic toxicity and accumulation of non-degradable particles in the brain significantly increases for patients with AD [36].”
Lin, X., Liu, W., Dong, X., & Sun, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.063 · Cited by 44 · cited 4×
“Their small size (less than 5 nm) and surface rich in functional groups allow them to interact effectively with A β -peptides, inhibiting their fibrillation and even disaggregating mature fibrils [77,79].”
InfluentialCai, J., Dao, P., Chen, H., Yan, L., Li, Y. L., Zhang, W., Li, L., Du, Z., Dong, C., & Meunier, B. (2019) · Dyes and Pigments · doi:10.1016/j.dyepig.2019.107968 · Cited by 43
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40 · cited 3×
“The accumulation of A β in the brain can be visualized in vivo using PET with FDA-approved radiopharmaceuticals [27,41]; approaches aimed at MRI diagnostics using magnetic Nps are also actively used [42].”
Multifunctional LUV Liposomes Decorated for BBB and Amyloid Targeting. A. In Vitro Proof-of-Concept
Papadia, K., Markoutsa, E., Mourtas, S., Giannou, A. D., La Ferla, B., Nicotra, F., Salmona, M., Klepetsanis, P., Stathopoulos, G. T., & Antimisiaris, S. G. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.019 · Cited by 40 · cited 3×
“Many represent parallel function combinations within single particles, where diagnostics and therapy operate independently [70,71,74].”
Xu, Y., Zhao, M.-N., Zhou, D., Zheng, T., & Zhang, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111360 · Cited by 38 · cited 1×
“Various types of nanoparticles (Nps) are used in research—both organic (lipid-based, polymeric) and inorganic (magnetic, gold, carbon-based) [20–22].”
Wei, Z., Dong, X., & Sun, Y. (2024) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.113907 · Cited by 36 · cited 5×
“The most common approach is the inhibition of A β aggregation and the disaggregation of already formed fibrils [29,68,77,79,81,84].”
InfluentialMullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32 · cited 2×
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than A β [49,51], making it a promising agent for targeted therapy delivery.”
Gu, Y., Zhang, Q., Huang, H., Ho, K. H. W., Zhang, Y., Yi, C., Zheng, Y., Chang, R. C. C., Wang, E. S., & Yang, M. (2024) · Theranostics · doi:10.7150/thno.98462 · Cited by 27 · cited 8×
“A significant portion of the studies use MRI with contrast agents based on gadolinium [70,71], SPIONs [58,63,73,83], or manganese ions [72], reflecting the researchers’ desire to create platforms potentially applicable in clinical practice.”
InfluentialJeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26 · cited 2×
“Recent advances include Food and Drug Administration (FDA)- approved anti-A β monoclonal antibodies (lecanemab, donanemab), which clear amyloid but yield limited slowing of cognitive decline and carry risks such as amyloid-related imaging abnormalities [15–17].”
Grosso, C., Silva, A., Delerue-Matos, C. M., & Barroso, M. F. (2023) · Pharmaceuticals · doi:10.3390/ph16121721 · Cited by 26 · cited 2×
“…biocompatibility [23–25]; polymeric particles (Poly(lactic-co-glycolic acid) (PLGA), dendrimers) provide biodegradability and functionalization [19,26]; superparamagnetic iron oxide Nps (SPIONs) enable MRI contrast and magnetic targeting [27]; and gold and carbon-based particles, including…”
Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26 · cited 3×
“A number of studies employ multimodal approaches, combining MRI with PET [64], SPECT [70,71], or fluorescence imaging [72,75], which compensates for the limitations of each method individually.”
Curcumin-Pluronic Nanoparticles: A Theranostic Nanoformulation for Alzheimer's Disease
Singh, A., Mahajan, S. D., Kutscher, H. L., Kim, S., & Prasad, P. N. (2020) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.2020034302 · Cited by 24 · cited 3×
“Encapsulation in ultrasmall (~11 nm) Pluronic F127 Nps increased brain accumulation 6.5-fold versus free curcumin while preserving amyloid plaque binding [40].”
InfluentialAlzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21 · cited 1×
“Tau hyperphosphorylation disrupts microtubule stability, promotes intraneuronal aggregates, synaptic dysfunction, and neuronal loss [5,6].”
Kim, S., Ma, X., Jeon, M. J., Song, S., Lee, J. S., Lee, J. U., Lee, C., Choi, S. H., & Sim, S. J. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116085 · Cited by 21 · cited 1×
“However, as noted in their review by Kim et al. [50], targeting tau pathology using Nps represents a promising strategy capable of restoring neuronal transmission and synaptic integrity.”
Liu, N., Liang, X., Yang, C., Hu, S., Luo, Q., & Luo, H. (2022) · Theranostics · doi:10.7150/thno.76574 · Cited by 21 · cited 4×
“These findings are not actually contradictory [67,68].”
InfluentialFrancisco, T. N., Malafaia, D., Melo, L., Silva, A. M. S., & Albuquerque, H. M. T. (2024) · ACS Omega · doi:10.1021/acsomega.3c10417 · Cited by 18 · cited 2×
“The most toxic forms of A β are not mature fibrils, but soluble oligomers [65].”
Leupe, H., Cauwenbergh, M., Cleeren, F., Dekervel, J., Verslype, C., & Deroose, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111608 · Cited by 15 · cited 1×
“A successful example is the radiopharmaceutical 177 Lu-DOTATAT, which simultaneously performs diagnostic and therapeutic functions in the treatment of neuroendocrine tumors [33].”
Advancing Nanomaterial-Based Strategies for Alzheimer’s Disease: A Perspective
Zhou, H., Yin, X., Zhang, G., Yang, Z., & Zhou, R. (2025) · JACS Au · doi:10.1021/jacsau.5c00002 · Cited by 15 · cited 3×
“…delivery, specific antibodies or vectors are also used, and the therapeutic effect is achieved by suppressing aggregation processes and enzymes that mediate hyperphosphorylation, stimulating autophagy, and using physical methods such as photodynamic dissociation of aggregates [21,55] (Figure 1).”
Self-Fluorescent Lone Tryptophan Nanoparticles as Theranostic Agents Against Alzheimer’s Disease
Sharma, M., Tiwari, V., Chaturvedi, S., Wahajuddin, M., Shukla, S., & Panda, J. J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01090 · Cited by 14 · cited 2×
“Also included in the selection were singular but promising developments, such as self-fluorescent tryptophan Nps [85], pyrimidine-based PET radioligands [86], and a charged dye molecule [84].”
Stögmann, E., & Schmidt, R. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02466-7 · Cited by 6 · cited 2×
“Recent advances include Food and Drug Administration (FDA)- approved anti-A β monoclonal antibodies (lecanemab, donanemab), which clear amyloid but yield limited slowing of cognitive decline and carry risks such as amyloid-related imaging abnormalities [15–17].”
Wei, Z., Dong, X., & Sun, Y. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c10137 · Cited by 5 · cited 5×
“Furthermore, many CDs exhibit antioxidant activity [78–80], positioning them an “all-in-one” platform for combination therapy.”
InfluentialBai, P., Gomm, A., Yoo, C., Mondal, P., Lobo, F. M., Meng, H., Zhou, Y., Xie, W., Wey, H., Tanzi, R. E., et al. (2025) · Advanced Science · doi:10.1002/advs.202414827 · Cited by 5 · cited 2×
“Pyrimidine-based PET radioligands [86] target the σ 1 receptor—a promising target involved in neuroprotection and neuroinflammation.”
Unveiling the theranostic potential of SPIONs in Alzheimer's disease management
Aminyavari, S., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., Sanati, M., & Sahebkar, A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.022 · Cited by 5 · cited 5×
“For SPIONs, diagnostic doses in vivo reach 5860 mg/kg, and therapeutic ones—25–100 mg/kg [92].”
InfluentialLiu, H., Guo, H., Fang, Y., Wang, L., & Li, P. (2024) · Molecules · doi:10.3390/molecules29102253 · Cited by 1
(2026, March 21). Dementia. Available online: https://www.who.int/news-room/fact-sheets/detail/dementia.
(n.d.)
UnresolvedAlzheimer’s Disease Facts and Figures
Better (2023) · Alzheimers Dement.
Unresolved18F PET with Flutemetamol for the Early Diagnosis of Alzheimer’s Disease Dementia and Other Dementias in People with Mild Cognitive Impairment (MCI)
Vernooij (2017) · Cochrane Database Syst. Rev.
Unresolved(2021). Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator for Mild to Moderate Cognitive Impairment Due to Alzheimer’s Disease (AD).
(n.d.)
Unresolved
Cited by
Targeted nanomedicine strategies for Alzheimer’s disease therapy
Ardah, M. T., Yaseen, B. M., Malathi, H., Ray, S., Thyagarajan, R., Shankhyan, A., Eshmetov, R., Ataullaev, Z., & Mishra, M. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04763-8 · Cited by 3
“In late-stage dementia, amyloid-only strategies are less likely to restore function unless paired with interventions that address Tau pathology, neuroinflammation, synaptic loss, mitochondrial injury, or neurovascular dysfunction [162, 163].”
Metadata
- Authors
- Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V.
- Affiliations
- Federal Medical Research Centre for Psychiatry and Narcology (RU)
- Corresponding author
- Zorkina, Yana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-04-16
- Volume
- 27
- Issue
- 8
- Pages
- 3560
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13115951
- OpenAlex
- W7154576422
- Cited by
- 1
- References
- 95
- Citations by year
- 2026: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-75-10063)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- Alzheimer's disease, theranostics, nanoplatforms, clinical translation, pharmacokinetics, temporal conflict, amyloid-beta oligomers, stimuli-responsive nanoparticles, brain drug delivery
- MeSH terms
- Theranostic Nanomedicine, Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.